Bilateral carcinoma in situ of the testis and cystic fibrosis transmembrane conductance regulator (CFTR) mutation in an azoospermic patient with late-onset 21β-hydroxylase deficiency

Journal of Endocrinological Investigation

Volumn 27, Issue 4, 2004, Pages 370-374

  Foppiani, Luca ^a   Baffico, M ^b   Lando, G ^c   Cappi, C ^a   De Cassan, P ^b   Patrosso, M C ^c   Vitali, A ^d   Penco, S ^c   Giusti, M ^a   Minuto, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SANTA CORONA HOSPITAL   (Italy)

Author keywords

21 hydroxylase deficiency; Carcinoma in situ; CFTR mutation; CYP21 mutation; Infertility

Indexed keywords

ALPHA FETOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHORIONIC GONADOTROPIN; DNA; FOLLITROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; LOOP DIURETIC AGENT; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; PROLINE; SERINE; STEROID 21 MONOOXYGENASE; TESTOSTERONE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ANAMNESIS; ARTICLE; AZOOSPERMIA; CANCER RADIOTHERAPY; CASE REPORT; CYSTIC FIBROSIS; DNA DETERMINATION; EXON; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HYPERTENSION; MALE; MALE INFERTILITY; PHYSICAL EXAMINATION; SEMEN ANALYSIS; SPERMATOGENESIS; STEROID 21 MONOOXYGENASE DEFICIENCY; TESTIS BIOPSY; TESTIS CARCINOMA;

EID: 2942587046     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03351065     Document Type: Article

References (20)

1. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Int Med 2002, 136: 463-70.
2. De Palma A, Vicari E, Palermo I, et al. Effects of cancer and anti-neoplastic treatment on the human testicular function. J Endocrinol Invest 2000, 23: 690-6.
3. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Canc 1996, 73: 1108-14.
4. Quinzi C, Castellani C. The cystic fibrosis transmembrane regulator gene and male infertility. J Endocrinol Invest 2000, 23: 684-9.
5. Jarvi K, McCallum S, Zielenski J. Heterogeneity of reproductive tract abnormalities in men with absence of the vas deferens: role of the cystic fibrosis transmembrane conductance regulator gene mutations. Fertil Steril 1998, 7: 724-8.
6. Sokol RZ. Infertility in men with cystic fibrosis. Curr Opin Pulm Med 2000, 17: 421-6.
7. Kalachans I, Rousso D, Goutzioulis F, Makedos G, Panidis D. Reversible infertility, pharmaceutical and spontaneous, in a male with late onset congenital adrenal hyperplasia, due to 21-hydroxylase deficiency. Arch Androl 2002, 48: 37-41.
8. Ojeifo JO, Winters SJ, Troen P. Basal and adrenocorticotropic hormone-stimulated serum 17α-hydroxyprogesterone in men with idiopathic infertility. Fertil Steril 1984, 42: 97-101.
9. Augarten A, Weissenberg R, Pariente C, Sack J. Reversible male infertility in late onset congenital adrenal hyperplasia. J Endocrinol Invest 1991, 14: 237-40.
10. Bonizzato A, Rolfini R, Cabrini G. Detection of cystic fibrosis mutations by reverse dot-blot hybridization. Eur J Lab Med 1999, 7: 117-22.
11. Daudin M, Bieth E, Bujan L, Massat G, Pontonnier F, Mieusset R. Congenital bilateral absence of the vas deferens: clinical characteristics, biological parameters, cystic fibrosis transmembrane conductance regulator gene mutations, and implications for genetic counsuelling. Fertil Steril 2000, 74: 1164-74.
12. Stuhrmann M, Dörk T. CFTR gene mutations and male infertility. Andrologia 2000, 32: 71-83.
13. Milunsky JM, Milusky A. Case report: cystic fibrosis and embryonal carcinoma of the testis. Am J Med Sci 1996, 311: 191-2.
14. Giwercman A, Petersen P. M. Cancer and male infertility. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 453-71.
15. Petersen PM, Giwercman A, Skakkebaek NE, Rorth M. Gonadal function in men with testicular cancer. Semin Oncol 1998, 25: 224-34.
16. Adesokan A, Adegboyega PA, Cowan DF, Kocurek J, Neal DE. Testicular "tumor" of the adrenogenital syndrome: a case report of an unusual association with the myelolipoma and seminoma in cryptoorchidism. J Clin Endocrinol Metab 1997, 80: 2120-7.
17. Brehm R, Marks A, Rey R, Kliesch S, Bergmann M, Steger K. Altered expression of connexins 26 and 43 in Sertoli cells in seminiferous tubules infiltrated with carcinoma in situ or seminoma. J Pathol 2002, 197: 647-53.
18. Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987, 47: 664-70.
19. Merke DP, Bornstein SR, Avila NA, Chrousos GP. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002, 136: 320-34.
20. Helmberg A, Luna MT, Tabarelli M, Kofler R, White P. R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. Mol Endocrinol 1992, 6: 1318-22.